Current Report Filing (8-k)
09 Mai 2022 - 1:27PM
Edgar (US Regulatory)
0001164888
false
0001164888
2022-05-05
2022-05-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): May 5, 2022
KYTO
TECHNOLOGY AND LIFE SCIENCE, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware |
|
000-50390 |
|
65-1086538 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
13050
La Paloma Road, Los Altos Hills, CA 94022
(Address
of Principal Executive Offices, and Zip Code)
650-204-7896
Registrant’s
Telephone Number, Including Area Code
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Termination
of Tender Offer
On
May 5, 2022, the Board of Directors of the Company (the “Board”) unanimously determined to terminate the Company’s
previously announced tender offer (the “Tender Offer”) to amend and exercise outstanding warrants for shares of common stock
(“Shares”). In determining to terminate the Tender Offer, the Board considered factors related to reassessment of offering
conditions.
The
Tender Offer was made pursuant to the Tender Offer Statement on Schedule TO that the Company originally filed with the U.S. Securities
and Exchange Commission on April 1, 2022, as amended. As a result of this termination, no Original Warrants will be amended, and all
Election Forms previously tendered and not withdrawn will be cancelled.
Item
9.01. | Financial
Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
|
|
Date:
May 6, 2022 |
By:
|
/s/
Paul Russo |
|
|
Paul
Russo Chief Executive Officer |
Kyto Technology and Life... (CE) (USOTC:KBPH)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Kyto Technology and Life... (CE) (USOTC:KBPH)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025